ArticleMolecular genetics and genomics : MGG2026
miR-133b induces antitumor immunity in cervical cancer through modulating CMTM6/PD-L1 axis.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune evasion mediated by the PD-L1 pathway remains a major hurdle in the effective treatment of cervical cancer (CC). While microRNAs (miRNAs) are known to critically regulate host immune responses, their specific roles in modulating the immunosuppressive microenvironment in CC remain largely elusive. Therefore, this study aims to elucidate the scope, clinical relevance, and mechanistic actions of the novel miR-133b/CMTM6/PD-L1 axis in cervical cancer immune evasion. Through a comprehensive series of in vitro and in vivo assays, we evaluated the expression and function of miR-133b, CMTM6, and PD-L1 in CC tissues and cell lines. Our results revealed that miR-133b is significantly downregulated in CC, which strongly correlates with poor patient prognosis. Mechanistically, miR-133b directly targets CMTM6, thereby suppressing PD-L1 expression. In clinical CC tissues, miR-133b levels were negatively correlated with both CMTM6 and PD-L1. Utilizing an immune-competent murine syngeneic model, we demonstrated that miR-133b overexpression profoundly inhibited tumor growth. This tumor suppression was accompanied by enhanced intra-tumoral infiltration of CD4
Indexed as
Identifiers
42301387What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.